Gilead lines up for a fast FDA OK with its next-gen hep C combo

Gilead lines up for a fast FDA OK with its next-gen hep C combo
Across three Phase III trials, a daily dose of Sovaldi and velpatasvir charted a 98% 12-week cure rate among patients with hep C genotypes 1 through 6, Gilead said. If approved, the fixed-dose pill could expand the company's multibillion-dollar hep C …
Read more here.

J&J's global deals team pursues a cure for hep B in latest partnering frenzy
"What we know from HIV and HCV, with chronic viruses, you need a combination therapy," says infectious disease chief Lawrence Blatt, who joined J&J after the pharma giant bought out his hep C biotech Alios for $ 1.75 billion. "We're trying to explore …
Read more here.

Why Hepatitis C Is Often Called 'The Silent Killer'
ORANGE (CBSLA.com) — Hepatitis C is often called “the silent epidemic” and “the silent killer.” Most of the people who have it, doctors say, don't realize they have it. People who have the virus might not look or even feel sick — for decades. It's …
Read more here.

Mumia's fight for medical treatment
In riveting testimony, Mumia's doctor, Dr. Joseph Harris, fully described how over the past two years these new antiviral drugs (marketed as Salvadi and Harvoni) have “revolutionized” the treatment of Hepatitis-C (HCV) with a 90-95 percent cure rate.
Read more here.

The bitterest pill for hepatitis C patients
At least one in 10 of the global population with hepatitis C lives in China. However, despite being available in most parts of the world, drugs known as "direct-acting antivirals", or DAAs, which can cure at least 95 per cent of cases, are not …
Read more here.

FDA Grants Priority Review to New Gilead Hep C Combo Tablet
The U.S. Food and Drug Administration (FDA) has granted priority review status to Gilead Sciences' investigational pangenotypic hepatitis C virus (HCV) fixed-dose combination tablet, which includes Sovaldi (sofosbuvir) and velpatasvir. The designation …
Read more here.

Expansion Waivers, Drug Pricing Among Top Medicaid Concerns
The new year also will bring continued efforts by primary care physicians, Medicaid health plans and the insurance industry to fight the pharmaceutical industry on the high cost of specialty and generic drugs, most notably those for hepatitis C. There …
Read more here.

The bitterest pill for hepatitis C patients
At least one in 10 of the global population with hepatitis C lives in China. However, despite being available in most parts of the world, drugs known as "direct-acting antivirals", or DAAs, which can cure at least 95 per cent of cases, are not …
Read more here.

Expansion Waivers, Drug Pricing Among Top Medicaid Concerns
The new year also will bring continued efforts by primary care physicians, Medicaid health plans and the insurance industry to fight the pharmaceutical industry on the high cost of specialty and generic drugs, most notably those for hepatitis C. There …
Read more here.

Why prescription drug prices are so hopelessly complex
They also looked at the discounts previously given to private payers for prior hepatitis C treatments and considered what the Solvaldi price would mean for future medicines. A second-wave drug, Harvoni, was in the works, and Gilead knew that the …
Read more here.


Leave a Reply